Fangzhou (6086) is a CN-listed Healthcare company in Drug Manufacturers - General with a market capitalization of HK
.1B, trading at HK$0.76 on the HKSE. This SniperIQ fundamentals page covers Fangzhou's valuation (P/E 73.7x, P/B 5.7x), profitability (net margin 0.3%), revenue (¥3.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapHK
.1B
P/E (TTM)73.7x
Net Margin0.3%
Revenue (FY25)¥3.5B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Fangzhou's market cap?
Fangzhou (6086) has a market capitalization of approximately HK
.1B, trading at HK$0.76 on the HKSE. Market cap moves with the live share price.
What is Fangzhou's P/E ratio?
Fangzhou's trailing twelve-month P/E ratio is 73.7x, with a price-to-book (P/B) of 5.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Fangzhou?
Fangzhou runs a net profit margin of 0.3%, a gross margin of 15.9%, and an operating margin of 0.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Fangzhou generate?
Fangzhou reported revenue of ¥3.5B for fiscal year 2025, with net income of ¥12M and earnings per share (EPS) of 0.0089. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Fangzhou pay a dividend?
Fangzhou does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Fangzhou financially healthy?
Fangzhou carries a debt-to-equity ratio of 0.23x and a current ratio of 1.20x, with a market beta of 0.86. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Fangzhou a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Fangzhou (6086) the key facts are: market cap HK
.1B, P/E 73.7x, revenue ¥3.5B, 52-week range 0.65-5.26. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Fangzhou's full fundamentals live
Get Fangzhou's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.